Comments
Pharma major Dr Reddy’s Laboratories Ltd has received approval from the United States Food & Drug Administration (USFDA) for its Azacitidine injection.
This is a bioequivalent generic version of VIDAZA (Azacitidine for injection) and is indicated in the treatment of some types of cancer and disorders that affect the bone marrow.
The launch of the product in the market is planned in the near-term, the Hyderabad-based company said in a release on Tuesday.
The VIDAZA brand had US sales of approximately $378.5 million for the most recent 12 months ending July 2013, according to IMS Health.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.